Skip to main content Accessibility help
×
Home
  • Print publication year: 2008
  • Online publication date: August 2010

27 - Ovarian Hyperstimulation Syndrome

from PART II - INFERTILITY EVALUATION AND TREATMENT

Summary

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication of ovulation induction, which may cause serious impact on the patient's health, with 0.1-2 percent of the patients developing severe forms of the syndrome. Many substances involved in the regulation of vascular permeability (VP) have been implicated in causing OHSS. The use of low doses of dopamine may be useful in severe OHSS patients. The OHSS primary prevention is to reduce its incidence, being the most important step to identify patients at risk that will undergo in-vitro fertilization (IVF) treatment, using a softer stimulation protocol and giving these patients special attention and close monitoring than usual with frequent ultrasound and serum estradiol levels. Until recently, OHSS treatment was reduced to the management of its complications. New data as the vascular endothelial growth factor (VEGF) system studies are providing new insights for prevention and treatment of OHSS.
REFERENCES
Navot, D., Bergh, P.A., Laufer, N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility (1992), 58, 249–61.
Rizk, B. Epidemiology of ovarian hyperstimulation syndrome: iatrogenic and spontaneous. In Rizk, B., (Ed.), Ovarian Hyperstimulation Syndrome. Cambridge, New YorkCambridge University Press (2006), Chapter 2, pp. 10–42.
Balasch, J., Fabregues, F., Arroyo, V. Peripheral arterial vasodilation hypothesis: a new insight into the pathogenesis of ovarian hyperstimulation syndrome. Human Reproduction, (1998) 13, 2718–30.
Rizk, B. Pathophysiology of hyperstimulation syndrome. In Rizk, B., (Ed.), Ovarian Hyperstimulation Syndrome. Cambridge, New YorkCambridge University Press (2006), Chapter 3, pp. 43–78.
Rizk, B. Ovarian hyperstimulation syndrome. In (Studd, J., Ed.), Progress in Obstetrics and Gynecology, Volume 11. EdinburghChurchill Livingtone (1993a), Chapter 18, pp. 311–49.
McClure, N., Leya, J., Radwanska, E., Rawlins, R., Haning, R.V. Luteal phase support and severe ovarian hyperstimulation syndrome. Human Reproduction, (1992) 7, 758–64.
Zalel, Y., Orvieto, R., Ben-Rafael, Z., Homburg, R., Fisher, O., Insler, V. Recurrent spontaneous ovarian hyperstimulation syndrome associated with polycystic ovary syndrome. Gynecologic Endocrinology, (1995) 9, 313–5.
Cappa, F., Pasqua, C., Tobia, M., Ventura, T. Ascites and hydrothorax due to endogenous hyperstimulation of H.C.G. in a case of hydatidiform mole destruens with secondary irreversible kidney insufficiency due to disseminated intravascular coagulation. Rivista Italiana di Ginecologia, (1976) 56, 363–8.
Guvenal, F., Guvenal, T., Timuroglu, Y., Timuroglu, T., Cetin, M. Spontaneous ovarian hyperstimulation-like reaction caused by primary hypothyroidism. Acta Obstetricia et Gynecologica Scandinavica, (2006) 85, 124–5.
Smits, G., Olatunbosun, O., Delbaere, A., Pierson, R., Vassart, G., Costagliola, S. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. New England Journal of Medicine, (2003) 21, 760–6.
Vasseur, C., Rodien, P., Beau, I., Desroches, A., Gerard, C., Poncheville, L., Chaplot, S., Savagner, F., Croue, A., Mathieu, E., Lahlou, N., Descamps, P., Misrahi, M. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. New England Journal of Medicine, (2003) 21, 753–9.
Montanelli, L., Delbaere, A., Di Carlo, C., Nappi, C., Smits, G., Vassart, G., Costagliola, S. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. The Journal of Clinical Endocrinology and Metabolism, (2004a)89, 1255–8.
Montanelli, L., Durme, J.J., Smits, G., Bonomi, M., Rodien, P., Devor, E.J., Moffat-Wilson, K., Pardo, L., Vassart, G., Costagliola, S. Modulation of ligand selectivity associated with activation of the transmembrane region of the human follitropin receptor. Molecular Endocrinology, (2004b)18, 2061–73.
Delbaere, A., Smits, G., Leener, A., Costagliola, S., Vassart, G. Understanding ovarian hyperstimulation syndrome. Endocrine, (2005) 26, 285–90.
Kihara, M., Sugita, T., Nagai, Y., Saeki, N., Tatsuno, I., Seki, K. Ovarian hyperstimulation caused by gonadotroph cell adenoma: a case report and review of the literature. Gynecological Endocrinology, (2006) 22, 110–3.
Lyons, C.A., Wheeler, C.A., Frishman, G.N., Hackett, R.J., Seifer, D.B., Haning, R.V. Jr. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Human Reproduction, (1994) 9, 792–9.
Pellicer, A., Albert, C., Mercader, A., Bonilla-Musoles, F., Remohí, J., Simón, C. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1α, interleukin-6, and vascular endothelial growth factor. Fertility and Sterility, (1999) 71, 482–9.
Rizk, B., Aboulghar, M. Modern management of ovarian hyperstimulation syndrome. Human Reproduction (1991) 6, 1082–7.
Schenker, J.G., Weinstein, D. Ovarian hyperstimulation syndrome: a current survey. Fertility and Sterility, (1978) 30, 255–68.
Knox, G.E. Antihistimine blockade of the ovarian hyperstimulation syndrome. American Journal of Obstetrics and Gynecology, (1974) 118, 992–4.
Navot, D., Margalioth, E.J., Laufer, N., Birkenfeld, A., Relou, A., Rosler, A., Schenker, J.G. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertility and Sterility, (1987) 48, 57–61.
Loret de Mola, J.R., Baumgardner, G.P., Goldfarb, J.E., Friedlander, M.A. Ovarian hyperstimulation syndrome: preovulatory serum concentrations of interleukin-6, interleukin-1 receptor antagonist and tumor necrosis factor-α cannot predict its occurrence. Human Reproduction, (1996) 7, 1377–80.
Aboulghar, M.A., Mansour, R.T., Serour, G.I., Elhelw, B.A., Shaarawy, M. Elevated levels of angiogenin in serum and ascitic fluid from patients with severe ovarian hyperstimulation syndrome. Human Reproduction, (1998) 13, 2068–71.
Magini, A., Granchi, S., Orlando, C., Vannelli, G.B., Pellegrini, S., Milani, S., Grappone, C., Franco, R., Susini, T., Forti, G., Maggi, M. Expression of endothelin-1 gene and protein in human granulosa cells. The Journal of Clinical Endocrinology and Metabolism, (1996) 81, 1428–33.
Fulghesu, A.M., Villa, P., Pavone, V., Guido, M., Apa, R., Caruso, A., Lanzone, A., Rossodivita, A., Mancuso, S. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism, (1997) 82, 644–8.
Senger, D.R., Galli, S.J., Dvorak, E., Perruzzi, C.A., Harvey, V.S., Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, (1983) 219, 983–5.
Rizk, B. Ovarian hyperstimulation syndrome. In Brindsen, P.R., Rainsbury, R.A., (Eds.), A Textbook of In Vitro Fertilization and Assisted Reproduction. Carnforth, UKParthenon Publishing (1992), Chapter 23, pp. 369–84.
Rizk, B., Aboulghar, N.A., Smitz, J. et al. The role of vascular endothelial growth factor and interleukins in the athogenesis of severe ovarian hyperstimulation syndrome. Human Reproduction Update, (1997) 3, 255–66.
Ujioka, T., Matsura, K., Tanaka, N., Okamura, H. Involvement of ovarian kinin-kallicrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model. Human Reproduction, (1998) 13, 3009–15.
Senger, D.R., Water, L., Brown, L.F., Nagy, J.A., Yeo, K.T., Yeo, T.K., Berse, B., Jackman, R.W., Dvorak, A.M., Dvorak, H.F. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Reviews, (1993) 12, 303–24.
Yan, Z., Weich, H.A., Bernart, W., Breckwoldt, M., Neulen, J. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. The Journal of Clinical Endocrinology and Metabolism, (1993) 77, 1723–5.
Senger, D.R., Connolly, D.T., Water, L., Feder, J., Dvorak, H.F. Purification and NH2-terminal amino acid sequence of guinea pig tumor secreted vascular permeability factor. Cancer Research (1990) 50, 1774–8.
Roberts, W.G., Palade, G.E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. Journal of Cell Science, (1995) 108, 2369–79.
Wei, M.H., Popescu, N.C., Lerman, M.I., Merrill, M.J., Zimonjic, D.B. Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Human Genetics, (1996) 97, 794–7.
Rizk, B. Genetics of ovarian hyperstimulation syndrome. In Rizk, B., (Ed.), Ovarian Hyperstimulation Syndrome. Cambridge, New YorkCambridge University Press (2006), Chapter 4, pp. 79–91.
Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. The FASEB Journal, (1999) 13, 9–22.
Watkins, R.H., D'Angio, C.T., Ryan, R.M., Patel, A., Maniscalco, W.M. Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury. The American Journal of Physiology, (1999) 276, 858–67.
Olson, T.A., Mohanraj, D., Carson, L.F., Ramakrishnan, S. VP factor gene expression in normal and neoplastic human ovaries. Cancer Research, (1994) 54, 276–80.
Gómez, R., Simón, C., Remohi, J., Pellicer, A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology, (2002) 143, 4339–48.
Shima, D.T., Kuroki, M., Deutsch, U., Ng, Y.S., Adamis, A.P., D'Amore, P.A. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. The Journal of Biological Chemistry, (1996) 271, 3877–83.
Burchardt, M., Burchardt, T., Chen, M.W., Shabsigh, A., Taille, A., Buttyan, R., Shabsigh, R. Expression of messenger ribonucleic acid splice variants for the vascular endothelial growth factor in the penis of adult rats and humans. Biology of Reproduction, (1999) 60, 398–404.
Neulen, J., Yan, Z., Raczek, S., Weindel, K., Keck, C., Weich, H.A., Marme, D., Breckwoldt, M. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/VP factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. The Journal of Clinical Endocrinology and Metabolism, (1995) 80, 1967–71.
Gordon, J.D., Mesiano, S., Zaloudek, C.J., Jaffe, R.B. Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. The Journal of Clinical Endocrinology and Metabolism, (1996) 81, 353–9.
Otani, N., Minami, S., Yamoto, M., Shikone, T., Otani, H., Nishiyama, R., Otani, T., Nakano, R. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. The Journal of Clinical Endocrinology and Metabolism, (1999) 84, 3845–51.
Yamamoto, S., Konishi, I., Tsuruta, E., Nanbu, K., Mandai, M., Kuroda, H., Matsushita, K., Hamid, A.A., Yura, Y., Mori, T. Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecologic Endocrinology, (1997) 11, 371–81.
Goldsman, M.P., Pedram, A., Domínguez, C.E., Ciuffardi, I., Levin, E., Asch, R.H. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertility and Sterility, (1995) 63, 268–72.
McClure, N., Healy, D.L., Rogers, P.A., Sullivan, J., Beaton, L., Haning, R.V. Jr., Connolly, D.T., Robertson, D.M. Vascular endothelial cell growth factor as permeability agent in ovarian hyperstimulation syndrome. Lancet, (1994) 344, 235–6.
Phillips, H.S., Hains, J., Leung, D.W., Ferrara, N. Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology, (1990) 127, 965–7.
Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N., Williams, L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, (1992) 255, 989–91.
Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., Heldin, C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. The Journal of Biological Chemistry, (1994) 269, 26988–95.
Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertsenstein, M., Wu, X.F., Breitman, M.L., Schuh, A.C. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice. Nature, (1995) 376, 62–6.
Verheul, H.M., Hoekman, K., Jorna, A.S., Smit, E.F., Pinedo, H.M. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist, (2000) 5, (Suppl. 1), 45–50.
Kendall, R.L., Wang, G., Thomas, K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, flt-1, and its heterodimerization with KDR. Biochemical and Biophysical Research Communications, (1996) 226, 324–8.
Hornig, C., Behn, T., Bartsch, W., Yayon, A., Weich, H.A. Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA. Journal of Immunological Methods, (1999) 226, 169–77.
Kendall, R.L., Thoma, K.A. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Proceedings of the National Academy of Sciences of the United States of America, (1993) 90, 10705–9.
Roeckle, W., Hecht, D., Sztajer, H., Waltenberger, J., Yayon, A., Weich, H.A. Differential binding characteristics and cellular inhibition by soluble VEGF receptor 1 and 2. Experimental Cell Research, (1998) 241, 161–70.
Xu, L., Yoneda, J., Herrera, C., Wood, J., Killion, J.J., Fidler, I.J. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. International Journal of Oncology, (2000) 16, 445–54.
Yukita, A., Asano, M., Okamoto, T., Mizutani, S., Suzuki, H. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Research, (2000) 20, 155–60.
Kobayashi, H., Okada, Y., Asahina, Gotoh, J., Terao, T. The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased VP associated with ovarian hyperstimulation syndrome. Journal of Molecular Endocrinology, (1998) 20, 363–74.
Agrawal, R., Tan, S.L., Wild, S., Sladkevicius, P., Engmann, L., Payne, N., Bekir, J., Campbell, S., Conway, G., Jacobs, H. Serum vascular endothelial growth factor concentrations in in-vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertility and Sterility, (1999) 71, 287–93.
Abramov, Y., Barac, V., Nisman, B., Schenker, J.G. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertility and Sterility, (1997) 67, 261–5.
Chen, C.D., Wu, M.Y., Chen, H.F., Chen, S.U., Ho, H.N., Yang, Y.S. Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome. Fertility and Sterility, (1999) 72, 286–92.
Albert, C., Garrido, N., Rao, C.V., Remohi, J., Simon, C., Pellicer, A. The role of the endothelium in the pathogenesis of ovarian hyperstimulation syndrome. Molecular Human Reproduction, (2002) 8, 409–18.
Wang, T.H., Horng, S.G., Chang, C.L., Wu, H.M., Tsai, Y.J., Wang, H.S., Soong, Y.K. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. Journal of Clinical Endocrinology and Metabolism, (2002) 87, 3300–08.
Antczak, M., Blerkom, J.The vascular character of ovarian follicular granulosa cells: phenotypic and functional evidence for an endothelial-like cell population. Human Reproduction, (2000) 15, 2306–18.
Ujioka, T., Matsuura, E., Kawano, T., Okamura, H. Role of progesterone in capillary permeability in hyperstimulated rats. Human Reproduction, (1997) 12, 1629–34.
Gómez, R., Simón, C., Remohi, J., Pellicer, A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biology of Reproduction, (2003) 68, 2164–71.
Brekken, R.A., Overholser, J.P., Stastny, V.A., Waltenberger, J., Minna, J.D., Thorpe, P.E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Research, (2000) 60, 5117–24.
Wedge, S.R., Ogilvie, D.J., Dukes, M., Kendrew, J., Curwen, J.O., Hennequin, L.F., Thomas, A.P., Stokes, E.S., Curry, B., Richmond, G.H., Wadsworth, P.F. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Research, (2000) 60, 970–5.
Vajkoczy, P., Menger, M.D., Vollmar, B., Schilling, L., Schmiedek, P., Hirth, K.P., Ullrich, A., Fong, T.A. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia, (1999) 1, 31–41.
Pau, E., Alonso-Muriel, I., Gómez, R., Novella, E., Ruiz, A., Garcia-Velasco, J.A., Simon, C., Pellicer, A. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Human Reproduction, (2006) 21, 1453–60. Epub (2006) Feb 17.
Villasante, A., Pacheco, A., Ruiz, A., Pellicer, A., Garcia-Velasco, J.A. Vascular endothelial cadherin regulates vascular permeability: implications for ovarian hyperstimulation syndrome. The Journal of Clinical Endocrinology and Metabolism, (2006) 10. [Epub ahead of print]
Enskog, A., Henriksson, M., Unander, M., Nilsson, L., Bränström, M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertility and Sterility, (1999) 71, 808–14.
Rizk, B., Smitz, J. Ovarian hyperstimulation syndrome after superovulation for IVF and related procedures. Human Reproduction (1992) 7, 320–7.
Rizk, B., Aboulghar, M.A. (1999). Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In Brinsden, P., (Ed.), A Textbook of In-vitro Fertilization and Assisted Reproduction, Second Edition. Canforth, UKThe Pathenon Publishing Group, Chapter 9, pp. 131–55.
Abramov, T., Elchalal, U., Schenker, J.G. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertility and Sterility, (1999) 71, 645–51.
Rizk, B. Complications of ovarian hyperstimulation syndrome. In Rizk, B., (Ed.), Ovarian Hyperstimulation Syndrome. Cambridge, New YorkCambridge University Press (2006), Chapter 5, pp. 92–118.
Fábregues, F., Balasch, J., Ginés, P., Manau, D., Jiménez, W., Arroyo, V., Creus, M., Vanrell, J.A. Ascites and liver test abnormalities during severe ovarian hyperstimulation syndrome. American Journal of Gastroenterology, (1999) 94, 994–9.
Balasch, J., Carmona, F., Llach, J., Arroyo, V., Jové, I., Vanrell, J.A. Acute prerrenal failure and liver dysfunction in a patient with severe ovarian hyperstimulation syndrome. Human Reproduction, (1990) 5, 348–51.
Gore, L., Nawar, M.G., Rizk, B. et al. Resistant unilateral hydrothorax as the sole manifestation of ovarian hyperstimulation syndrome. Middle East Fertility Society Journal, (2002) 7, 149–53.
Kingsland, C, Collins, JV, Rizk, B, Mason, B. Ovarian hyperstimulation presenting as acute hydrothorax after in-vitro fertilization. American Journal of Obstetric and Gynecology, (1989) 16, 381–2.
Pellicer, A., Valbuena, D., Cano, F., Remohí, J., Simón, C. Lower implantation rates in high responders: evidence for an altered endocrine milieu during the preimplantation period. Fertility and Sterility, (1996) 65, 1190–5.
Simón, C., Garcia-Velasco, J.A., Valbuena, D., Peinado, J.A., Moreno, C., Remohí, J., Pellicer, A. Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating hormone step-down regimen. Fertility and Sterility, (1998) 70, 234–9.
Aboulghar, M.A., Mansour, R.T., Serour, G.I., Ramzy, A.M., Amin, Y.M. Oocyte quality in patients with severe ovarian hyperstimulation syndrome (OHSS). Fertility and Sterility, (1997) 68, 1017–21.
Cano, F., García-Velasco, J.A., Millet, A., Remohí, J., Simón, C., Pellicer, A. Oocyte quality in polycystic ovaries revisited: identification of a particular subgroup of women. Journal of Assisted Reproduction and Genetics, (1997) 14, 254–61.
Rimington, M.R., Walker, S.M., Shaw, R.W. The use of laparoscopic ovarian electrocautery in preventing cancellation of in vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Human Reproduction, (1997) 12, 1443–7.
Rizk, B., Nawar, M.G. Laparoscopic ovarian drilling for surgical induction of ovulation in polycystic ovarian syndrome. In Allahbadia, G. (Ed.), Manual of Ovulation Induction. Mumbai, India Rotunda Medical Technologies (2001), Chapter 18, pp. 140–4.
Rizk, B. Prevention of ovarian hyperstimulation syndrome. In Rizk, B., (Ed.), Ovarian Hyperstimulation Syndrome. Cambridge, New YorkCambridge University Press (2006), Chapter 7, pp. 130–99.
Garcia-Velasco, J.A., Zuniga, A., Pacheco, A., Gómez, R., Simon, C., Remohi, J., Pellicer, A. Coasting acts through downregulation of VEGF gene expression and protein secretion. Human Reproduction, (2004) 19, 1530–8.
Garcia-Velasco, J.A., Isaza, V., Quea, G., Pellicer, A. Coasting for the prevention of ovarian hyperstimulation syndrome: much to do about nothing?Fertility and Sterility, (2006) 85, 547–54.
Fluker, M.R., Hooper, W.M., Yuzpe, A.A.Withholding gonadotropins (“coasting”) to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles. Fertility and Sterility, (1999) 71, 294–301.
Rizk, B. Coasting for the prevention of threatening OHSS: An American Perspective. In Gerris, J., Oliveness, F., Delvigne, A., (Eds.) Ovarian Hyperstimulation Syndrome. Tayler and Francis (2006), Chapter 23, pp. 247–67.
Rizk, B., Thorneycroft, I.H. Does recombinant follicle stimulating hormone abolish the risk of severe ovarian hyperstimulation syndrome?Fertility and Sterility, (1996) 65, S151–2.
Egbase, P.E., Maksheed, M., Sharhan, M.A., Grudzinskas, J.G. Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective, randomized study. Human Reproduction, (1997) 12, 2603–6.
Tomazevic, T., Meden-Vrtovec, H.Early timed follicular aspiration prevents severe ovarian hyperstimulation syndrome. Journal of Assisted Reproduction and Genetics, (1996)13, 282–6.
Orvieto, R., Ben-Rafael, Z. Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. Human Reproduction, (1998) 98, 3306–9.
König, E., Bussen, S., Sütterlin, M., Steck, T. Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. Human Reproduction, (1998) 13, 2421–4.
Bellver, J., Munoz, E.A., Ballesteros, A., Soares, S.R., Bosch, E., Simon, C., Pellicer, A., Remohi, J. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Human Reproduction, (2003) 18, 2283–8.
Awonuga, A.O., Dean, N., Zaidi, J., Pittrof, R.U., Bekir, J.S., Tan, S.L. Outcome of frozen embryo replacement cycles following elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome. Journal of Assisted Reproduction and Genetics, (1996) 13, 293–7.
Shaker, A.G., Zosmer, A., Dean, N., Bekir, J.S., Jacobs, H.S., Tan, S.L. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertility and Sterility, (1996) 65, 992–6.
Zelinski-Wooten, M.B., Hutchison, J.S., Hess, D.L., Wolf, D.P., Stouffer, R.L. A bolus of recombinant human follicle stimulating hormone at midcycle induces periovulatory events following multiple follicular development in macaques. Human Reproduction, (1998) 13, 554–60.
Rizk, B. Ovarian hyperstimulation syndrome: prediction, prevention, and management. In Rizk, B., Devroey, P., Meldrum, D.R., (Eds.), Advances and Controversies in Ovulation Induction. 34th ASRM Annual Postgraduate Program, Middle East Fertility Society Precongress Course. ASRM, 57th Annual Meeting, Orlando, FL, Birmingham, Alabamathe American Society for Reproductive Medicine (2001), pp. 23–46.
Rizk, B. Can OHSS in ART be eliminated? In Rizk, B., Meldrum, D., Schoolcraft, W., (Eds.), A Clinical Step-by-Step Course for Assisted Reproductive Technologies. 35th ASRM Annual Postgraduate Program, Middle East Fertility Society Precongress Course. ASRM 58th Annual Meeting, Seattle, WA, Birmingham, AlabamaThe American Society for Reproductive Medicine (2002), pp. 65–102.
Shalev, E., Geslevich, Y., Ben-Ami, M. Induction of pre-ovulatory luteinizing hormone surge by gonadotropin-releasing hormone agonist for women at risk of developing the ovarian hyperstimulation syndrome. Human Reproduction, (1994) 9, 417–19.
Rizk, B.Nawar, M.G. Ovarian hyperstimulation syndrome. In Serhal, P., Overton, C. (Eds.), Good Clinical Practice in Assisted Reproduction. Cambridge, UKCambridge University Press (2004), Chapter 8, pp. 146–66.
Morris, R.S., Karande, V.C., Didkiewicz, A., Morris, J.L., Gleicher, N. Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome. Fertility and Sterility, (1999) 71, 452–6.
Jong, D., Macklon, N.S., Mannaerts, B.M., Coelingh Bennink, H.J., Fauser, B.C. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization. Human Reproduction, (1998) 13, 573–5.
Gal, M., Eldar-Geva, T., Margalioth, E.J., Barr, I., Orly, J., Diamant, Y.Z. Attenuation of ovarian response by low-dose ketoconazole during superovulation in patients with polycystic ovary syndrome. Fertility and Sterility, (1999) 72, 26–31.
Balasch, J., Fábregues, F., Arroyo, V., Jiménez, W., Creus, M., Vanrell, J.A. Treatment of severe ovarian hyperstimulation syndrome by a conservative medical approach. Acta Obstetricia et Gynecologica Scandinavica, (1996) 75, 662–7.
Aboulghar, M.A., Mansour, R.T., Serour, G.I., Amin, Y.M. Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome. Fertility and Sterility, (1990) 53, 933–5.
Al-Ramahi, M., Leader, A., Claman, P., Spence, J. A novel approach to the treatment of ascites associated with ovarian hyperstimulation syndrome. Human Reproduction, (1997) 12, 2614–16.
Koike, T., Araki, S., Minakami, H., Ogawa, S., Sayama, M., Shibahara, H., Sato, I. Clinical efficacy of peritoneovenous shunting for the treatment of severe ovarian hyperstimulation syndrome. Human Reproduction, (2000) 15, 113–7.
Ferraretti, A.P., Gianaroli, L., Diotallevi, L., Festi, C., Trounson, A. Dopamine treatment for severe ovarian hyperstimulation syndrome. Human Reproduction, (1992) 7, 180–3.
Kodama, H., Fukuda, J., Karube, H., Matsui, T., Shimizu, T., Tanaka, T. Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism. Fertility and Sterility, (1995) 64, 1207–9.
Marx, G.M., Steer, C.B., Harper, P., Pavlakis, N., Rixe, O., Khayat, D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!Journal of Clinical Oncology, (2002) 20, 1446–8.
Glade-Bender, J., Kandel, J.J., Yamashiro, D.J. VEGF blocking therapy in the treatment of cancer. Expert Opinion on Biological Therapy, (2003) 3, 263–76.
Kuenen, B.C., Tabernero, J., Baselga, J. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clinical Cancer Research, (2003) 9, 1648–55.
Basu, S., Nagy, J.A., Pal, S., Vasile, E., Eckelhoefer, I.A., Bliss, V.S., Manseau, E.J., Dasgupta, P.S., Dvorak, H.F., Mukhopadhyay, D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nature Medicine, (2001) 7, 569–74.
Sarkar, C., Chakroborty, D., Mitra, R.B. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. American Journal of Physiology, Heart and Circulatory Physiology, (2004) 287, H1554–60.
Quinn, T.P., Peters, K.G., Vries, C., Ferrara, N., Williams, L.T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proceedings of the National Academy of Sciences of the United States of America, (1993) 90, 7533–7.
Gomez, R., Gonzalez-Izquierdo, M., Zimmermann, R.C., Novella- Maestre, E., Alonso-Muriel, I., Sanchez-Criado, J., Remohi, J., Simon, C., Pellicer, A. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2- dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology, (2006) 147, 5400–11.
Tsunoda, T., Shibahara, H., Hirano, Y., Suzuki, T., Fujiwara, H., Takamizawa, S., Ogawa, S., Motoyama, M., Suzuki, M. Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecolgical Endocrinology, (2003) 17, 281–6.
Manno, M., Tomei, F., Marchesan, E., Adamo, V. Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome?European Journal of Obstetrics, Gynecology, and Reproductive Biology, (2005) 122, 127–8.
Papaleo, E., Doldi, N., Santis, L., Marelli, G., Marsiglio, E., Rofena, S., Ferrari, A. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Human Reproduction, (2001) 16, 2263–6.
Shimon, I., Rubenek, T., Bar-Hava, I., Nass, D., Hadani, M., Amsterdam, A., Harel, H. Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma. Journal of Clinical Endocrinology and Metabolism, (2001) 86, 3635–40.
Christin-Maitre, S., Rongiéres-Bertrand, C., Kottler, M.L., Lahlou, N., Frydman, R., Touraine, P., Bouchard, P. A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma. Journal of Clinical Endocrinology and Metabolism, (1988) 83, 3450–3.
Gómez, R., González, M., Simón, C., Remohi, J., Pellicer, A. Tyroxine hydroxylase (TH) downregulation in hyperstimulated ovaries reveals the dopamine agonist bromocriptine (Br2) as an effective and specific method to block increased vascular permeability (VP) in OHSS. Fertility and Sterility, (2003) 80, (Suppl. 3), 43–4.
Murata, Y., Ando, H., Nagasaka, T., Takahashi, I., Saito, K., Fukugaki, H., Matsuzawa, K., Mizutani, S. Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma. Journal of Clinical Endocrinology and Metabolism, (2003) 88, 1988–93.
Knoepfelmacher, M., Danilovic, D.L., Rosa Nasser, R.H., Mendonca, B.B. Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas. Fertility and Sterility, (2006) 86, 719.
Alvarez, C., Bosch, E., Melo, M.A.B., Fernández-Sánchez, M., Muñoz, J., Remohí, J., Simón, C., Pellicer, A. The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients. Human Reproduction, (2006) 21 (Suppl. 1), i96.